Alfa Wassermann Company Profile

05:33 EST 10th December 2018 | BioPortfolio



Phone: 39.085.8571226
Fax: 39.085.8543128

News Articles [68 Associated News Articles listed on BioPortfolio]

Alfa Wassermann SpA Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 12042018] Prices from USD $250

SummaryAlfa Wassermann SpA Alfa Wassermann, a subsidiary of AlfaSigma SpA is a pharmaceutical company which produces and distributes drugs for human health. The company provides new discoveries in med...

Human medicines European public assessment report (EPAR): Pergoveris, follitropin alfa / lutropin alfa, Revision: 12, Authorised

New Zealand to fund only biosimilar epoetin alfa

New Zealand will stop funding the brand-name epoetin alfa biological Eprex and, in future, will only fund the biosimilar epoetin alfa Binocrit.

Epoetin Alfa Biosimilar Launched in United States at Discounted Cost

Epoetin alfa-epbx (Retacrit), the biosimilar to epoetin alfa (Procrit/Epogen) has been launched in the United States at a significant discount.

Pending EC decision: Epoetin Alfa Hexal, epoetin alfa, Opinion date: 26-Jul-2018

Alfa Laval Wins SEK 120 Million Energy Efficiency Order

"Alfa Laval offers an extensive product range of heat exchangers with one important thing in common; they are all highly efficient and thereby contribute to Read more...

Verticroft - Alfa Hay Price Continues to Rise - 200 USD by 2019

DUBAI, UAE, October 1, 2018 /PRNewswire/ -- Verticroft, a world leader in VCC (vertical crop culture) and the largest producer of sustainable Alfa hay in Read more...

ESA Biosimilar Effective for Anemia in Hemodialysis Patients

Researchers found "no clinically meaningful differences" in efficacy and safety between the biosimilar epoetin alfa-epbx and epoetin alfa.

Drugs and Medications [59 Associated Drugs and Medications listed on BioPortfolio]

Ribavirin [Aurobindo Pharma Limited]

These highlights do not include all the information needed to use ribavirin safely and effectively. See full prescribing information for ribavirin tablets. Ribavirin Tablets Initial U.S. Approval: 200...

Ribavirin [Sandoz Inc]

These highlights do not include all the information needed to use RIBAVIRIN TABLETS safely and effectively. See full prescribing information for RIBAVIRIN TABLETS. Ribavirin Tablets, oralInitial U.S. ...

Ribavirin [Cadila Healthcare Limited]

These highlights do not include all the information needed to use ribavirin safely and effectively. See full prescribing information for ribavirin. Initial U.S. Approval: 2002

Ribavirin [Zydus Pharmaceuticals (USA) Inc.]

These highlights do not include all the information needed to use ribavirin safely and effectively. See full prescribing information for ribavirin. Initial U.S. Approval: 2002

Ribasphere ribapak [Three Rivers Pharmaceuticals, LLC]

These highlights do not include all the information needed to use Ribasphere (ribavirin, USP) safely and effectively. See full prescribing information for Ribasphere (ribavirin, USP). Ribasphere (riba...

PubMed Articles [46 Associated PubMed Articles listed on BioPortfolio]

Switching from Epoetin Alfa (Epogen®) to Epoetin Alfa-Epbx (RetacritTM) Using a Specified Dosing Algorithm: A Randomized, Non-Inferiority Study in Adults on Hemodialysis.

For patients with anemia undergoing hemodialysis, erythropoiesis-stimulating agents (ESAs) are typically dosed via precise algorithms. Using one such algorithm, we assessed the maintenance of hemoglob...

Ovarian stimulation with corifollitropin alfa followed by hp-hMG compared to hp-hMG in patients at risk of poor ovarian response undergoing ICSI: A randomized controlled trial.

To compare the results of two ovarian stimulation protocols for IVF in patients at risk of poor ovarian response: corifollitropin alfa followed by hp-hMG versus daily administration of hp-hMG. We inte...

Correction to: Andexanet Alfa: First Global Approval.

The article Andexanet Alfa: First Global Approval, written by Young-A Heo, was originally published Online First without open access.

An easy-to-use baseline scoring system to predict response to peginterferon alfa-2a in patients with chronic hepatitis B in resource-limited settings.

Approximately one-third of patients have durable responses after finite (48-week) treatment with peginterferon alfa-2a. The ability to identify patients likely to respond would be particularly useful ...

HBsAg loss with Pegylated-interferon alfa-2a in hepatitis B patients with partial response to nucleos(t)-ide analog: new switch study.

Hepatitis B surface antigen (HBsAg) loss is seldom achieved with nucleos(t)ide analog (NA) therapy in chronic hepatitis B patients but may be enhanced by switching to finite pegylated-interferon (Peg-...

Clinical Trials [919 Associated Clinical Trials listed on BioPortfolio]

Study Comparing Reduction and Viral Safety of IFN Alfa-2b XL + Ribavirin Versus PEG IFN Alfa-2b + Ribavirin in Patients With Chronic Hepatitis C Genotype 1

The purpose of this study is to confirm if IFN alfa-2b XL has a better antiviral activity and tolerability as compared with current marketed reference, while combined with ribavirin, in a ...

Cost-effectiveness Study of Epoetin Alfa and Darbepoetin Alfa in Adult Patients With Cancer Who Have Anemia

The purpose of this study is to evaluate the cost-effectiveness of epoetin alfa compared with darbepoetin alfa in the treatment of anemia in adults receiving chemotherapy for cancer. Epoe...

PROCRIT Extended Dosing For Maintenance of Hemoglobin in Pre-Dialysis CKD Patients

The purpose of this study is to demonstrate that once every-2-weeks and once every-4-weeks treatment with epoetin alfa, a drug that increases red blood cell production, in patients with an...

Corifollitropin Alfa Combined With Menotropin Versus Follitropin and Lutropin Alfa in Expected Suboptimal Responders

In an opened randomized study of women undergoing in vitro fertilization with expected suboptimal response to controlled ovarian stimulation (Poseidon Group 2b) investigators will examine ...

Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy

RATIONALE: Epoetin alfa and darbepoetin alfa may cause the body to make more red blood cells. They are used to treat anemia caused by chemotherapy in patients with cancer. PURPOSE: This r...

Companies [26 Associated Companies listed on BioPortfolio]

Alfa Wassermann, Inc

Under one name or another, Alfa Wassermann, Inc. has provided high quality products and services to the health care community since 1960. Our parent company, the Alfa Wassermann Group, headquartered i...

Alfa Wassermann


Alfa Scientific Designs, Inc.

Alfa Scientific Designs, Inc. is a leader in the development and manufacture of rapid, immunoassay, point-of-care tests. As a minority, woman-owned, small business, ALFA offers a ...

Assisted Living Federation of America (ALFA)

The Assisted Living Federation of America (ALFA) is the largest national association exclusively dedicated to professionally managed assisted living communities and the seniors an...

Alfa Laval

Alfa Laval is a leading global provider of specialized products and engineered solutions. Our equipment, systems and services are dedicated to helping customers to optimize the performance of their pr...

More Information about "Alfa Wassermann" on BioPortfolio

We have published hundreds of Alfa Wassermann news stories on BioPortfolio along with dozens of Alfa Wassermann Clinical Trials and PubMed Articles about Alfa Wassermann for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Alfa Wassermann Companies in our database. You can also find out about relevant Alfa Wassermann Drugs and Medications on this site too.

Quick Search


Corporate Database Quicklinks

Searches Linking to this Company Record